China Healthcare | Asia Pacific January 28, 2026 05:41 PM GMT M Idea China Pharma – 2025 Earnings Preview & Initial 2026 Outlook Hengrui remains our Top Pick – we expect its product sales growth to accelerate in 2026, new deal momentum to be sustained, and more milestones to kick in. Globalization will remain a key investment theme, in particular pipeline advances and option exercise by partners to unlock milestone flows. Key Takeaways Related report: Catalyst Preview - China Pharma. See inside for: With th ...

BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index. The inclusion will become effective prior to the opening of trading on Friday, January 30, 2026. Launched in 1994, the S&P SmallCap 600 Index is one of the most widely followed benchmarks for U.S. small-capitalization equities. The index is commonly used by active managers and small-cap investors seeking exposure t ...

Key Takeaways Trump warned tariffs on South Korean goods could jump to 25%, sparking concerns over South Korean ETFs.Hyundai Motor faces heavy exposure, with autos making up 27% of Korea's U.S. exports.EWY holds major stakes in Samsung Electronics and SK Hynix, leaving funds sensitive to trade outcomes. U.S. President Donald Trump has once again reignited global trade tensions by threatening to hike tariffs on South Korean imports from 15% to 25%, in an announcement on Truth Social. In a move that caught Se ...

Summary of Option Care Health FY Conference Call Company Overview - **Company**: Option Care Health (NasdaqGS: OPCH) - **Industry**: Healthcare Services, specifically Home Infusion Therapy Key Financial Highlights - **Preliminary Results for 2024**: - Revenue growth of approximately **13%** - Adjusted EBITDA growth of about **6%** - Adjusted EPS growth of around **10%** at the midpoint [5][18] - **Patient Census**: Served over **315,000 unique patients** during the year [5] - **2026 Guidance**: - Revenue growth projected at **4%** - EBITDA growth expected at **5%** - Diluted EPS growth anticipated at **7%** [19] Strategic Initiatives - **M&A Activity**: Successful acquisition of **Intramed Plus**, enhancing market presence in the Southeast [6] - **Investment Focus**: Continued investments in infusion clinics, pharmacies, and operational models to build a national network while maintaining local responsiveness [7][10] - **Share Repurchase Program**: Expansion of share repurchase authorization as part of capital deployment strategy [9] Market Position and Competitive Advantage - **National Scale with Local Responsiveness**: Over **190 locations** and **750 infusion chairs** across the U.S., providing broad market access with **96% coverage** of the U.S. population through **800 payer relationships** [10][11] - **Diversified Product Portfolio**: Over **600 therapies** in the formulary, with **88% of revenue** coming from commercial counterparts [14][15] - **Strong Cash Flow Generation**: Allows for reinvestment in business and flexibility in capital allocation [12] Industry Dynamics and Challenges - **Impact of Biosimilars**: Anticipated revenue headwinds from **Stelara** and related biosimilars, estimated at **$25-$35 million** [20][21] - **Shift to Home Infusion**: Increasing demand for home infusion services as a cost-effective alternative to hospital settings, with potential savings of **20%-30%** compared to hospital outpatient departments [41] Future Growth Opportunities - **Chronic vs. Acute Growth**: Expected higher growth in chronic therapies compared to acute therapies, with a focus on leveraging investments for efficiency [36] - **Emerging Therapy Areas**: Interest in neurological disorders, gastroenterology, and oncology as potential growth areas, with ongoing discussions with pharmaceutical manufacturers [47][51] Technological Advancements - **AI Utilization**: Partnership with Palantir to streamline administrative processes and improve operational efficiency, focusing on enhancing workforce productivity without displacing jobs [58][59] Conclusion - **Strong Foundation**: The company emphasizes its solid foundation and ability to deliver value to patients, payers, and pharmaceutical partners, positioning itself well for sustainable growth moving forward [67][68]

Core Insights - Cencora, Inc. (COR) is positioned for growth due to a strong U.S. Healthcare Solutions business and new product launches, although competition remains a concern [1][8] - The company's shares have increased by 13.4% over the past six months, outperforming the industry gain of 12.1% and the S&P 500 Index increase of 13.6% [1] Company Overview - Cencora is one of the largest pharmaceutical service companies globally, focusing on drug distribution and related services to lower healthcare costs and enhance patient outcomes, with a market capitalization of $67.15 billion [2] Financial Performance - The bottom line for Cencora is expected to improve by 11.9% over the next five years, with earnings surpassing estimates in the last four quarters, averaging a surprise of 5.51% [3] Positive Growth Drivers - Cencora benefits from sustained pharmaceutical utilization trends, particularly in specialty drugs for oncology and retina, supported by favorable demographics and ongoing pharmaceutical innovations [4] - As a leading distributor aligned with top manufacturers, Cencora is well-positioned for long-term organic operating income growth of 6-9% [5] - The expansion into management services organizations (MSOs) enhances growth and strategic positioning, allowing for higher-value services and reinforcing Cencora's pharmaceutical-centric strategy [6] Market Dynamics - The rising adoption of biosimilars in the Part B market is a significant profitability driver, generating higher margins than branded products, which supports operating income expansion [10] - Strong physician adoption in oncology and retina reinforces the benefits of biosimilars, positioning Cencora to capitalize on ongoing innovation and product transitions [11] Challenges - The international segment is experiencing declines due to reduced clinical trial activity and a slower recovery in biotech services, with operating income down 2% in the fourth quarter of fiscal 2025 [12] - Although GLP-1 sales remain strong, growth has moderated to 19%, and the loss of a low-margin grocery-channel customer is impacting revenue growth, leading to a revised U.S. revenue outlook [13] Estimate Trends - There has been a positive estimate revision trend for fiscal 2026, with the Zacks Consensus Estimate for earnings increasing from $17.59 to $17.62 per share, and first-quarter fiscal 2026 revenues expected to improve by 5.4% year-over-year [14]

Core Insights - Viatris Inc. (NASDAQ:VTRS) is recognized as one of the 14 Best Pharma Dividend Stocks to Buy in 2026 [1] - Barclays initiated coverage of Viatris with an Overweight rating and a price target of $15, indicating improving investor sentiment in the pharmaceutical sector [2] - Viatris announced a definitive agreement to sell its equity stake in Biocon Biologics Limited for a total consideration of $815 million, which includes $400 million in cash and $415 million in newly issued equity shares [3] Company Overview - Viatris Inc. is a global pharmaceutical company that offers a diverse range of medicines, including generics, branded drugs, biosimilars, OTC products, and active pharmaceutical ingredients (APIs) [4]

Group 1 - Teva Pharmaceutical focuses on producing generic drugs, which allows it to benefit from revenue streams when patent protections on original drugs expire [2][3] - The company holds a 35% market share in its home market of Israel, indicating a highly competitive environment in the generics sector [4] - Teva is attempting to differentiate itself by producing harder-to-make generic drugs, which aligns with its technological strengths and aims to protect its profit margins [5][6] Group 2 - The shift towards more complex generic drugs, including biosimilars, introduces additional regulatory challenges and risks, but is seen as a strategy for long-term growth [6][7]

PresentationI'm pleased to introduce the CEO of the company; Robert Wessman, the CFO of the company; Linda Jonsdottir, the CEO; Joseph McClellan, and the Head of Investor Relations, which is Patrik Ling. There is one page in the presentation with the convertible bond terms. We can go through that afterwards. There will also be a Q&A session [Operator Instructions].Robert WessmanCEO, Founder & Executive Chairman Yes. Thank you so much. First of all, I want to thank you, everyone, for joining in here today, a ...

Biopharma Business Growth and Strategy - Fresenius' Biopharma business is rapidly scaling, with revenue increasing from €04 billion in 2022 to an estimated >€08 billion in 2025[23, 24] - The company aims to approximately double its Biopharma revenue by 2030, targeting a ~20% EBIT margin[42, 43] - The global biosimilars market is projected to grow sixfold by 2035, reaching >€180 billion[19, 48] Manufacturing and Cost Leadership - Fresenius is investing >€300 million over the next 5 years to expand Biopharma manufacturing capacity and drive growth[122] - The company's vertical integration strategy, particularly through mAbxience, provides a competitive advantage, covering ~75% of manufacturing costs[64] - Fresenius aims to increase internal Drug Substance (DS) manufacturing to >60% of total capacity required by 2030[130] Portfolio and R&D - Fresenius has a competitive portfolio and pipeline covering €200 billion in originator sales[82, 89] - The company targets 2+ molecules per year entering development through in-house R&D and strategic in-licensing[82, 88] - Fresenius' US tocilizumab biosimilar, Tyenne, has achieved a market share of ~18% as of September 2025[163] Commercial Excellence - Fresenius is expanding its commercial presence in the US, with revenue growth of >60% expected from 2024 to 2025[161] - The company is implementing a targeted go-to-market strategy, molecule by molecule, to optimize market access and contracting[151, 165] - Fresenius has a strong European core with direct sales in >20 markets and deep payer access[157]

Core Insights - The transaction involves the sale of the Just - Evotec Biologics manufacturing site in Toulouse for approximately US$ 350 million in cash, along with upfront technology license fees for Evotec's continuous manufacturing platform [1] - Evotec is eligible for additional license fees and development revenues, including success-based milestones, which could exceed US$ 300 million in the coming years [1] - The agreement covers royalties on a portfolio of up to ten biosimilars, targeting over US$ 90 billion in originator net sales, enhancing Evotec's revenue mix and profit margins [1] Financial Impact - The sale is immediately earnings accretive, improving Evotec's short, mid, and long-term revenue mix and capital efficiency [1] - Total potential payments from the transaction may exceed US$ 650 million, in addition to royalties from up to ten biosimilar molecules, six of which have an originator net sales value of US$ 90 billion [1] Transaction Details - The agreement was finalized following a non-binding term-sheet in July and a contract signing in November, with the effective date of the transaction being December 5, 2025 [1] - The buyer of the Toulouse site is Sandoz AG, which will benefit from Evotec's continuous manufacturing platform technology [1]